Immune Checkpoint Inhibitor-Related Adrenal Insufficiency

被引:3
作者
Cherry, Grace [1 ]
机构
[1] UCLA, Hlth Melanoma Program, 100 Med Plaza,Suite 550, Los Angeles, CA 90095 USA
关键词
Oncology nurses; Immune Checkpoint Inhibitor-Related Adrenal; Insufficiency; Case study; Evidence-cased; Clinical reflection; DIAGNOSIS;
D O I
10.1016/j.soncn.2021.151131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: It is an exciting time in oncology nursing as new treatments are continually emerging to improve oncological outcomes for people affected by cancer. Immunotherapy is one such innovation in contemporary oncology practice, but the side effects of its treatment can be life threatening. Oncology nurses must be educated in the early identification of life-threatening side effects, and deliver evidence-based interventions to manage consequences of therapy such as, immune checkpoint inhibitor-related adrenal insufficiency. Data Source: This article utilizes a case study to emphasize the need for early identification and interventions for clinical management of immunotherapy related adrenal insufficiency. A review of the current evidence is included to provide recommendations for oncology nurses who are involved in providing care for people affected by cancer receiving immunotherapy. Implications for Nursing Practice: Oncology nurses are the frontline caregivers to assess, recognize, so that early intervention and treament can lead to optimal patient outcomes. Conclusion: Adrenal insufficiency is a life-threatening condition that is difficult to diagnose but if recognized early, morbidity can be prevented, quality of life improved, treatment initiated and life saving immunotherapy treatment can safely continue. Oncology nurses play an active role in ensuring the safe administration of immunotherapy by recognizing this important immune related adverse event. I would like to give credit to Patricia Jakel, RN, MSN, UCLA CNS and Dr. Melissa Lechner, UCLA endocrinologist for their invaluable input in this article. (c) 2021 Published by Elsevier Inc.
引用
收藏
页数:6
相关论文
共 18 条
  • [1] [Anonymous], 2021, NCCN GUID VERS 1 202
  • [2] Diagnosis and management of adrenal insufficiency
    Bancos, Irina
    Hahner, Stefanie
    Tomlinson, Jeremy
    Arlt, Wiebke
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (03) : 216 - 226
  • [3] Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
    Barroso-Sousa, Romualdo
    Barry, William T.
    Garrido-Castro, Ana C.
    Hodi, F. Stephen
    Min, Le
    Krop, Ian E.
    Tolaney, Sara M.
    [J]. JAMA ONCOLOGY, 2018, 4 (02) : 173 - 182
  • [4] Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
    Bornstein, Stefan R.
    Allolio, Bruno
    Arlt, Wiebke
    Barthel, Andreas
    Don-Wauchope, Andrew
    Hammer, Gary D.
    Husebye, Eystein S.
    Merke, Deborah P.
    Murad, M. Hassan
    Stratakis, Constantine A.
    Torpy, David J.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (02) : 364 - 389
  • [5] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [6] Campbell M., 2021, PHYSL ENDOCRINE HORM
  • [7] Cancer Research Institute, 2021, FDA APPR TIM ACT IMM
  • [8] Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer
    Chang, Jeremy
    Tran, Jeffrey
    Kamel, Dina
    Basu, Arnab
    [J]. BMJ CASE REPORTS, 2019, 12 (03)
  • [9] Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
    Corsello, Salvatore Maria
    Barnabei, Agnese
    Marchetti, Paolo
    De Vecchis, Liana
    Salvatori, Roberto
    Torino, Francesco
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) : 1361 - 1375
  • [10] Deligiorgi M, 2021, Expert Opin Biol Ther.